Patents by Inventor Lalgudi S. Harikrishnan

Lalgudi S. Harikrishnan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONISTS OF ROR GAMMAt
    Publication number: 20230295087
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: May 8, 2020
    Publication date: September 21, 2023
    Inventors: Lalgudi S. Harikrishnan, Brian E. Fink, Patrice Gill, Lan-Ying Qin, Muthoni G. Kamau, Tram N. Huynh, Ashok Vinayak Purandare, Honghe Wan, Daniel O’Malley
  • AGONISTS OF ROR GAMMAt
    Publication number: 20230242478
    Abstract: The present invention is directed to compounds of the formula [INSERT CHEMICAL STRUCTURE HERE}] wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 3, 2023
    Inventors: Lalgudi S. Harikrishnan, Muthoni G. Kamau, Brian E. Fink
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11667663
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: June 6, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lalgudi S. Harikrishnan, Muthoni G. Kamau, Xiao Zhu
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11660311
    Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: May 30, 2023
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Yufen Zhao, Lan-Ying Qin, Zheming Ruan, Lalgudi S. Harikrishnan, Muthoni G. Kamau
  • AGONISTS OF ROR GAMMAt
    Publication number: 20220306630
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: August 5, 2020
    Publication date: September 29, 2022
    Inventors: Lalgudi S. Harikrishnan, Peter Kinam Park, Zheming Ruan, Donna D. Wei, Daniel O'Malley, Honghe Wan, Ashok Vinayak Purandare, Brian E. Fink
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11339185
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: May 24, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20220117995
    Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 21, 2022
    Inventors: Brian E. FINK, Dharmpal S. Dodd, Yufen Zhao, Lan-Ying Qin, Zheming Ruan, Lalgudi S. Harikrishnan, Muthoni G. Kamau
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20200270298
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: August 30, 2018
    Publication date: August 27, 2020
    Inventors: Lalgudi S. HARIKRISHNAN, Muthoni G. Kamau, Xiao Zhu
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10744150
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: August 18, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Lan-ying Qin, Zheming Ruan, Yufen Zhao, Lalgudi S. Harikrishnan, Muthoni G. Kamau, Steven J. Walker
  • Tricyclic compounds as anticancer agents
    Patent number: 10683290
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: June 16, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Claude A. Quesnelle, Lalgudi S. Harikrishnan, Matthew D. Hill
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20200079815
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 12, 2020
    Inventors: Brian E. FINK, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G, Kamau, Lalgudi S. Harikrishnan
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10519187
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: December 31, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • TGF beta receptor antagonists
    Patent number: 10399987
    Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 3, 2019
    Assignee: Bristol-Myer Squibb Company
    Inventors: Lalgudi S. Harikrishnan, Brian E. Fink, Robert M. Borzilleri, Gopikishan Tonukunuru, Jayakumar Sankara Warrier
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20190248828
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 15, 2019
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • TGF? receptor antagonist
    Patent number: 10336761
    Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF? R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: July 2, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lalgudi S. Harikrishnan, Brian E. Fink, Robert M. Borzilleri, Gopikishan Tonukunuru, Hasibur Rahaman, Jayakumar Sankara Warrier, Balaji Seshadri
  • TGF beta receptor antagonists
    Patent number: 10292985
    Abstract: The invention relates generally to compounds that modulate the activity of TGFBETA R-1 and TGFBETA R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: May 21, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Brian E. Fink, Lalgudi S. Harikrishnan, Jayakumar Sankara Warrier
  • Carbazole compounds useful as bromodomain inhibitors
    Patent number: 10196387
    Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: February 5, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Poss, David R. Tortolani, Ashok Vinayak Purandare, John S. Tokarski, Christopher P. Mussari, Muthoni G. Kamau, Dharmpal S. Dodd, Ashvinikumar V. Gavai, Daniel O'Malley, Tram N. Huynh, Wayne Vaccaro, Lalgudi S. Harikrishnan
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20190030057
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 27, 2018
    Publication date: January 31, 2019
    Inventors: Brian E. FINK, Dharmpal S. Dodd, Lan-ying Qin, Zheming Ruan, Yufen Zhao, Lalgudi S. Harikrishnan, Muthoni G. Kamau
  • TGF BETA RECEPTOR ANTAGONISTS
    Publication number: 20180250303
    Abstract: The invention relates generally to compounds of formula (I) that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: August 23, 2016
    Publication date: September 6, 2018
    Inventors: Robert M. Borzilleri, Brian E. Fink, Lalgudi S. Harikrishnan, Upender Velaparthi, Vishweshwaraiah Baligar, Hasibur Rahaman, Jayakumar Sankara Warrier
  • TGF BETA RECEPTOR ANTAGONISTS
    Publication number: 20180243312
    Abstract: The invention relates generally to compounds that modulate the activity of TGFBETA R-1 and TGFBETA R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: August 30, 2016
    Publication date: August 30, 2018
    Inventors: Robert M. BORZILLERI, Brian E. Fink, Lalgudi S. Harikrishnan, Jayakumar Sankara Warrier